The effect of fecal occult-blood screening on the incidence of colorectal cancer.

By J. Mandel, T. Church, J. Bond, F. Ederer, Mindy S. Geisser, S. Mongin, D. Snover, L. Schuman. New England Journal of Medicine, 2000

1,448 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/1a452161f1f827c15548baf51795aa1eeacd5948

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Stephen A. Feig
2. S. Fedewa
3. L. Matrisian
4. Robert A. Smith
5. R. Siegel
6. Douglas Rex
7. A. Jemal

Citations in the corpus

• Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society (2018, background): “There is variability in prevention potential among the available screening tests, but all noncolonoscopy screening tests contribute to prevention through colonoscopy follow-up and adenoma removal after a positive initial screening test, as demonstrated by the reduction in incidence in the US guaiac ”
• Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update (2008, background): “However, the number of positive screening tests that were followed by an adequate examination (either colonoscopy or flexible sigmoidoscopy and DCBE) was reported as 8,663 for the annual and 5,170 for the biennial screening groups (31).”
• Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force (2002, background): “The 18-year follow-up also showed that the incidence of colorectal cancer decreased by 20% (CI, 10% to 30%) and 17% (CI, 6% to 27%) in the groups screened annually and biennially, respectively, compared with controls (16).”
• Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer (2002, background): “Colonoscopy and polypectomy have been effective in reducing the incidence of colorectal cancer in cohort studies (1–3), a case control study (4), a randomized controlled trial ( 5 ), and a trial of fecal occult blood testing (6).”
• Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force (2008, result): “Both models have been validated against the long-term reductions in incidence and mortality of colorectal cancer with annual FOBT reported in the Minnesota Colon Cancer Control Study (3, 25, 26) and show good concordance with the trial results.”
• Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * † (2008, background): “124 –126 High-quality CSPY depends on (1) appropriate training and experience; (2) proper documentation of risk assessment; (3) complete exam to the cecum with adequate mucosal visualization and bowel preparation; (4) ability to detect and remove polyps safely; (5) documentation of polypoid lesions ”
• Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. (2011, background): “CRC incidence was also reduced in one of the trials (2), which may have resulted from endoscopic polypectomy of neoplasms in people detected with a positive test.”
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. (2014, background): “Colorectal cancer incidence rates have declined since the mid 1980s, and randomized clinical trials demonstrated that fecal occultblood screening is effective in decreasing incidence of colorectal cancer (9).”
• Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. (2008, background): “124 –126 High-quality CSPY depends on (1) appropriate training and experience; (2) proper documentation of risk assessment; (3) complete exam to the cecum with adequate mucosal visualization and bowel preparation; (4) ability to detect and remove polyps safely; (5) documentation of polypoid lesions ”
• Meta-analyses of Colorectal Cancer Risk Factors (2013, neutral): “as screening [3–16].”